SCHEMBL3564976

SCHEMBL3564976

O=C(O)Cc1cc(OCc2ccccc2)cc(-c2ccc(Cl)c(Cl)c2)c1

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.50
BCL2L1 Q07817 2/20 0.50
LTB4R Q15722 2/20 0.50
LTB4R2 Q9NPC1 2/20 0.50
MRGPRX4 Q96LA9 1/20 0.47
PPARG P37231 1/20 0.47
PPARD Q03181 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
CFD P00746 1/20 0.46
GSTP1 P09211 1/20 0.45
FFAR1 O14842 3/20 0.43
FFAR4 Q5NUL3 2/20 0.43
AKR1B1 P15121 1/20 0.43
PTGDR2 Q9Y5Y4 2/20 0.43
PTGER1 P34995 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3572558 0.87 PPARD (0.53) MCL1BCL2L1LTB4RLTB4R2MRGPRX4
SCHEMBL3567119 0.86 LTB4R (0.53) MCL1BCL2L1LTB4RLTB4R2MRGPRX4
SCHEMBL3569632 0.85 PPARG (0.62) MCL1LTB4RLTB4R2MRGPRX4PPARG
SCHEMBL3569938 0.85 CFD (0.51) MCL1BCL2L1LTB4RLTB4R2MRGPRX4
SCHEMBL3578107 0.84 PPARG (0.55) MCL1LTB4RLTB4R2PPARGPPARD
SCHEMBL3575842 0.82 FFAR1 (0.55) MCL1LTB4RLTB4R2PPARGPPARD
SCHEMBL3576903 0.82 CFD (0.53) LTB4RLTB4R2MRGPRX4PPARGPPARD
SCHEMBL3576743 0.82 MRGPRX4 (0.54) MCL1BCL2L1LTB4RLTB4R2MRGPRX4
SCHEMBL3569849 0.81 PPARD (0.56) MCL1LTB4RLTB4R2MRGPRX4PPARG
SCHEMBL2957881 0.81 MEN1 (0.67) LTB4RLTB4R2MEN1KMT2AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US claimed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US claimed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP claimed
US-7825160-B2 such as [5-(4-Fluoro-benzyloxy)-4'-trifluoromethyl-biphenyl-3-yl]-acetic acid, used for the treatment of Alzheimer's disease and for the modulation of gamma -secretase activity CELLZOME LIMITED (GB) 2010-11-02 US disclosed
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof CELLZOME AG (DE) 2009-05-07 US disclosed
EP-1805129-B1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME LTD (GB) 2009-03-18 EP disclosed
EP-1805129-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2007-07-11 EP disclosed
WO-2006045554-A1 (BIPHENYL) CARBOXYLIC ACIDS AND DERIVATIVES THEREOF CELLZOME AG (DE) 2006-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118289-A1 (Biphenyl) Carboxylic Acids and Derivatives Thereof BACE1, BACE2, APP MCL1 3306/4885BCL2L1 883/4885LTB4R 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.